Comparing three Electrode Placements to Optimize ECT

比较三种电极放置以优化 ECT

基本信息

项目摘要

DESCRIPTION (provided by applicant): Electroconvulsive therapy remains an important treatment for severely depressed patients who do not respond adequately to, or are intolerant of, antidepressant medication. As the prevalence of major depression increases, particularly in the geriatric population, the need for effective treatments is an urgent public health concern. Despite refinements in technique, the cognitive impairment associated with ECT remains a serious concern for many patients. Traditionally, ECT has been administered with one of two standard techniques: 1) bilateral (bitemporal) electrode placement or 2) right unilateral electrode placement. Bilateral electrode placement has greater efficacy but causes more cognitive impairment, while right unilateral electrode placement is less effective for some patients but causes less cognitive impairment. Recently, two innovative techniques have shown promise in preliminary studies: 1) right unilateral ECT administered at much higher electrical dose, which may achieve efficacy equivalent to bilateral ECT and 2) a novel electrode placement (bifrontal) which may combine the beneficial properties of both bilateral and unilateral ECT. We propose a double blind, randomized, controlled clinical trial comparing the standard technique of bilateral ECT with two novel techniques - high-dose unilateral ECT and bifrontal ECT. The primary aims of the study are to compare the three treatments in terms of 1) antidepressant efficacy and 2) cognitive effects during and at the end of the treatment course, and over a two-month naturalistic follow-up period. An additional aim is to compare the treatments in terms of quality of life over two months. In this study, 360 patients with major depression are randomized over 4 years at 4 sites. Assessments are the Hamilton Rating Scale for Depression (HRSD), a comprehensive neuropsychological test battery, and quality of life outcome measures. Provisions are made for assuring the ongoing quality of treatments and assessments. The investigators are experienced ECT providers and researchers who are now successfully collaborating on an ongoing NIMH-funded trial of continuation ECT vs. pharmacotherapy (MH55489, MH55486, MH55484). The proposed study will be the first direct comparison of the three types of ECT and will inform psychiatrists about the optimal technique of ECT. The results of this study will promote more effective and safer treatment of the most severely ill depressed patients.
描述(由申请方提供):电休克治疗仍然是对抗抑郁药物反应不充分或不耐受的严重抑郁患者的重要治疗方法。 随着重度抑郁症患病率的增加,特别是在老年人群中,对有效治疗的需求是一个紧迫的公共卫生问题。 尽管技术上有所改进,但与ECT相关的认知障碍仍然是许多患者的严重问题。 传统上,ECT采用两种标准技术之一进行管理:1)双侧(双颞)电极放置或2)右侧单侧电极放置。 双侧电极放置具有更大的疗效,但引起更多的认知障碍,而右侧单侧电极放置对某些患者的疗效较差,但引起的认知障碍较少。 最近,两种创新技术在初步研究中显示出前景:1)以高得多的电剂量给予右侧单侧ECT,其可实现与双侧ECT相当的疗效; 2)新型电极放置(双额叶),其可联合收割机双侧和单侧ECT的有益特性。 我们提出了一个双盲,随机,对照临床试验比较标准技术的双边ECT与两种新的技术-高剂量单侧ECT和双额叶ECT。 该研究的主要目的是比较三种治疗方法在1)抗抑郁疗效和2)治疗过程中和治疗结束时的认知效果,以及两个月的自然随访期。 另一个目的是比较两个月内的生活质量。 在这项研究中,360例重性抑郁症患者在4年内随机分布在4个地点。 评估是汉密尔顿抑郁量表(HRSD),一个全面的神经心理测试电池,和生活质量的结果措施。 为保证治疗和评估的持续质量作出了规定。 研究人员是经验丰富的ECT提供者和研究人员,他们现在正在成功地合作进行一项由NIMH资助的持续ECT与药物治疗(MH 55489,MH 55486,MH 55484)的试验。 这项拟议中的研究将是第一次直接比较三种类型的ECT,并将告知精神科医生ECT的最佳技术。 这项研究的结果将促进对最严重的抑郁症患者进行更有效、更安全的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles H Kellner其他文献

762. The Mortality Rate of Electroconvulsive Therapy: Results from a Systematic Review and Meta-Analysis
  • DOI:
    10.1016/j.biopsych.2017.02.829
  • 发表时间:
    2017-05-15
  • 期刊:
  • 影响因子:
  • 作者:
    Nina Torring;Sohag N Sanghani;Georgios Petrides;Charles H Kellner;Soren Dinesen Ostergaard
  • 通讯作者:
    Soren Dinesen Ostergaard
Pulsewidth in ECT: a reminder that efficacy trumps tolerability
ECT 中的脉冲宽度:提醒功效胜过耐受性
  • DOI:
    10.1080/08039488.2023.2292245
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    1.8
  • 作者:
    Charles H Kellner;M. B. Jørgensen
  • 通讯作者:
    M. B. Jørgensen
UPDATE ON ELECTROCONVULSIVE THERAPY IN GERIATRIC DEPRESSION: Session 300
  • DOI:
    10.1016/j.jagp.2019.01.163
  • 发表时间:
    2019-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Adriana P. Hermida;Charles H Kellner;Georgios Petrides;William Maffitt McDonald;William Vaughn McCall
  • 通讯作者:
    William Vaughn McCall
Electroconvulsive Therapy Changes Immunological Markers in Patients With Major Depressive Disorder: A Scoping Review.
电休克疗法改变重度抑郁症患者的免疫标志物:范围界定审查。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Jonathan R Young;Mariah K Evans;Julie Hwang;Michael D Kritzer;Charles H Kellner;Richard D. Weiner
  • 通讯作者:
    Richard D. Weiner
Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients.
氟伏沙明、丙咪嗪和安慰剂对抑郁症门诊患者儿茶酚胺功能的影响。
  • DOI:
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Michael R. Johnson;R. Lydiard;W. Morton;L. K. Laird;Thomas E. Steele;Charles H Kellner;James C. Ballenger
  • 通讯作者:
    James C. Ballenger

Charles H Kellner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles H Kellner', 18)}}的其他基金

1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    8460575
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    8536526
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    8241159
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    8053779
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    7901026
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
1/8-Prolonging Remission in Depressed Elderly (PRIDE)
1/8-延长抑郁老年人的缓解期 (PRIDE)
  • 批准号:
    7652954
  • 财政年份:
    2009
  • 资助金额:
    $ 19.22万
  • 项目类别:
Comparing three Electrode Placements to Optimize ECT
比较三种电极放置以优化 ECT
  • 批准号:
    6899201
  • 财政年份:
    2002
  • 资助金额:
    $ 19.22万
  • 项目类别:
Comparing three Electrode Placements to Optimize ECT
比较三种电极放置以优化 ECT
  • 批准号:
    6661206
  • 财政年份:
    2002
  • 资助金额:
    $ 19.22万
  • 项目类别:
Comparing three Electrode Placements to Optimize ECT
比较三种电极放置以优化 ECT
  • 批准号:
    6757862
  • 财政年份:
    2002
  • 资助金额:
    $ 19.22万
  • 项目类别:
Continuation ECT vs Pharmacotherapy: Efficacy and Safety
持续 ECT 与药物治疗:疗效和安全性
  • 批准号:
    6472500
  • 财政年份:
    1997
  • 资助金额:
    $ 19.22万
  • 项目类别:

相似海外基金

From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
  • 批准号:
    MR/Y013050/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
  • 批准号:
    495575
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Operating Grants
Core B: Clinical Trials Core
核心 B:临床试验核心
  • 批准号:
    10554476
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
  • 批准号:
    2884930
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
  • 批准号:
    10855627
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
  • 批准号:
    10895949
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
  • 批准号:
    10891325
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
  • 批准号:
    10761602
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
  • 批准号:
    10758129
  • 财政年份:
    2023
  • 资助金额:
    $ 19.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了